UBS has raised its price target for Sartorius Stedim Biotech to 215 euros, while keeping a "Neutral" rating on the stock. The adjustment is due to higher valuations in the biotechnology sector following the company's third-quarter results.

Sartorius Stedim shares were trading at 199.10 euros, down 0.43%. The stock has experienced fluctuations, reaching a high of 280.80 euros and a low of 141.70 euros. Different trading platforms reported slight variations in the stock price, with Xetra showing a price of 202.00 euros, while Frankfurt and Stuttgart reported prices around 199 euros.

The updated target and market performance reflect the changing landscape of the biotechnology industry, with investors closely monitoring the company's trajectory and broader market trends.